Tumor pretargeting in mice using MORF conjugated CC49 antibody and radiolabeled complimentary cMORF effector.
about
Pretargeted imaging and radioimmunotherapy of cancer using antibodies and bioorthogonal chemistryComparing two TAG-72 binding peptides previously identified by phage display as potential imaging agents.Adding a clearing agent to pretargeting does not lower the tumor accumulation of the effector as predicted.A preclinical 188Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49.Human islet cell MORF/cMORF pretargeting in a xenogeneic murine transplant model90Y labeled phosphorodiamidate morpholino oligomer for pretargeting radiotherapy.Addressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery.Quantitative Correlation of in Vivo Properties with in Vitro Assay Results: The in Vitro Binding of a Biotin-DNA Analogue Modifier with Streptavidin Predicts the in Vivo Avidin-Induced Clearability of the Analogue-Modified Antibody.Intraperitoneal injection is not always a suitable alternative to intravenous injection for radiotherapy(99m)Tc-MORF oligomers specific for bacterial ribosomal RNA as potential specific infection imaging agentsComparison between two labeled agents in mice using a coinjection-ratio approach in contrast to a conventional group approach.The ratio of maximum percent tumour accumulations of the pretargeting agent and the radiolabelled effector is independent of tumour size.Rules of thumb for maximum percent tumor accumulation
P2860
Q27026010-F026DB01-99FF-4F01-9FCD-834A09BC6ACEQ34005190-867814E2-45A1-4E5C-B5CD-3BF7A17DF348Q34519414-FD43F823-3456-4C11-9383-91845E6016BBQ34979175-633D3E0F-233C-4D78-8C58-7B8EB3EA296EQ35028182-FD938A1E-4EBD-4B97-88C6-DD49E340FAEDQ35629379-537C7754-C944-47D5-B520-08A856C157C2Q36395999-E3D55D65-1AF3-45E8-81EB-3BD38A1D801BQ36458382-BF3772B4-2DF5-48B2-8196-B00F15227CD0Q36842135-EA558801-F909-4E8F-A382-E76496473B69Q37304150-7D83F6ED-521A-48DA-A11D-D16538DCA620Q37373494-BCC1D353-E987-4267-8DCB-5C354DFFC235Q37481714-A542D9EE-6069-4E28-85C3-255F4D6B3E75Q39375117-7141F5E6-2E1D-46DE-8850-CD6C5D898729
P2860
Tumor pretargeting in mice using MORF conjugated CC49 antibody and radiolabeled complimentary cMORF effector.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Tumor pretargeting in mice usi ...... complimentary cMORF effector.
@ast
Tumor pretargeting in mice usi ...... complimentary cMORF effector.
@en
Tumor pretargeting in mice usi ...... complimentary cMORF effector.
@nl
type
label
Tumor pretargeting in mice usi ...... complimentary cMORF effector.
@ast
Tumor pretargeting in mice usi ...... complimentary cMORF effector.
@en
Tumor pretargeting in mice usi ...... complimentary cMORF effector.
@nl
prefLabel
Tumor pretargeting in mice usi ...... complimentary cMORF effector.
@ast
Tumor pretargeting in mice usi ...... complimentary cMORF effector.
@en
Tumor pretargeting in mice usi ...... complimentary cMORF effector.
@nl
P2093
P2860
P1476
Tumor pretargeting in mice usi ...... complimentary cMORF effector.
@en
P2093
D J Hnatowich
M Rusckowski
P H Pretorius
P2860
P304
P577
2009-12-15T00:00:00Z